We turn scientific
 knowledge into new possibilities for life

Some discoveries expand what we know,

others expand what is possible.
At Ombú, we work to help both go further.

Grupo

from bench
to people

We develop new ways to intervene where no solutions exist today.

Two ways of doing it

brecover

B recover

The first regenerative therapy for ischemic stroke.

A new possibility where treatment ends or never existed.

In preclinical development. Moving toward First-in-Human.

bliving

B Living

Dietary supplements designed to accompany your health through scientific innovation.

Science on your side.

Currently in development. Coming soon.

Philosophy

What is born from all of us
returns to all of us

Science is a collective effort.

No discovery happens in isolation. It is built on generations of accumulated knowledge, public education, research, collaboration, and time.

That is why we believe knowledge should not remain where it is created. It should return to the people who made it possible.

From bench to people

We help discoveries reach people.

Componente –

Ombú

Discovery becomes possibility. For people.

Componente –

People

Questions become knowledge.

Componente –

Education

Knowledge becomes capability.

Componente –

Research

Capability becomes discovery.

TEAM

Science has a human story too.

Merari Tumin Chevalier
P

Dr. Merari Tumin Chevalier

Founder & CEO

Ombú was born from a simple belief: knowledge can go further.
After years of research in biomaterials, Merari set out to turn science into action.

Built together

We bring together scientific, clinical and strategic expertise to build solutions with real-world impact.

Team

Janice Chevalier
P

Janice Chantal Chevalier

CFO (Chief Financial Officer)

Dr. José Martinez Orgado
P

Dr. José Martinez Orgado

CMO (Chief Medical Officer)

Antonia Lorca
P

Antonia Lorca Olivares

Junior Business Development Associate

Flavia Bern
P

Dr. Flavia Bern Barbehito

Junior Regulatory Affairs Associate

Scientific Advisory Board

Prof. Abhay Pandit
P

Prof. Abhay Pandit

Prof. José Carlos Rodríguez Cabello
P

Prof. José Carlos Rodríguez Cabello

Dr. Matilde Alonso Rodrigo
P

Prof. Matilde Alonso Rodrigo

Contact

Let’s continue the conversation.

Science moves forward through collaboration, shared knowledge and new ideas. If you’d like to learn more about our work or explore ways to work together, we’d love to hear from you.

Telephone +34 655 996 750
Email info@ombues.com
LinkedIn Ombú
Merari Tumin Chevalier

Dr. Merari Tumin Chevalier, PhD, MBA

Founder & CEO

A chemist and PhD in Materials Science specializing in biomaerials, with training in business administration, Merari built her career developing nanotherapies and polymeric hydrogels for tissue regeneration, with an emphasis on their application in cardiovascular diseases. Her path took her from international academic research to technology entrepreneurship. She leads Ombú by combining scientific rigor with business vision to advance health solutions, with a focus on B recover, the first regenerative therapy aimed at all survivors of ischemic stroke.

Q
Janice Chevalier

Janice Chantal Chevalier

CFO (Chief Financial Officer)

She studied Economics and Commercialization, with additional training in international business and business management. She brings solid experience in financial management, commercial operations, foreign trade, and innovation. Her approach combines operational efficiency with a strong sensitivity to social impact and environmental sustainability, aligning with Ombú's vision of building science that reaches the market with purpose.

Q
Dr. José Martinez Orgado

Dr. José Martinez Orgado

CMO (Chief Medical Officer)

Head of Neonatology at Hospital Clínico San Carlos and Associate Professor of Pediatrics at UCM, Dr. Martínez Orgado brings extensive clinical and research experience in neonatal neurology and neuroprotection, with particular expertise in translating novel therapeutics from bench to bedside. His clinical authority in neonatal, adult stroke and brain injury anchors Ombú's regulatory and translational strategy, ensuring B recover's development stays grounded in real-world patient need.

Q
Antonia Lorca

Antonia Lorca Olivares

Junior Business Development Associate

A graduate in Business Administration and Management with a Master's degree in Marketing, Antonia combines analytical rigor, creativity, and strategic vision in business development. She stands out for her communication skills, her ability to manage complex processes, and her passion for bringing visibility to solutions that deliver real value to society. She drives the growth of Ombú's various business units with a hybrid perspective that bridges commercial strategy and market trends.

Q
Flavia Bern

Dr. Flavia Bern Barbehito

Junior Regulatory Affairs Associate

A medical doctor with a Master's degree in the Pharmaceutical Industry focused on pharmacovigilance, compliance, and regulatory affairs, Flavia combines her clinical training with a genuine curiosity for research and scientific development, bringing a rigorous perspective on the safety and quality of the health solutions Ombú offers. Her commitment to agile problem-solving in the face of uncertainty makes her a natural bridge between science, regulation, and the patient. Her work helps ensure that Ombú meets the highest regulatory and safety standards.

Q
Prof. Abhay Pandit

Prof. Abhay Pandit

Scientific Advisory Board

Professor Abhay Pandit is the Director of CÚRAM, Research Ireland Centre for Medical Devices, and an Established Professor of Biomaterials at the University of Galway. His research focuses on developing advanced biomaterial platforms for targeted delivery of biomolecules to aid molecular and cellular repair. He is particularly interested in optimizing biomaterial substrates for glycomodulating biomolecules to treat rare eye diseases, aiming to restore cell physiology, immune balance, vascularization, neural function, and signaling in corneal pathology.

His work has contributed to the development of biomaterial platforms for neural, musculoskeletal, and cardiovascular applications, many of which have been validated for clinical use. He has published over 400 peer-reviewed papers leading to a h-index of 70, filed numerous patents, and licensed four technologies to medical device companies. Prof. Pandit has also secured €90M in research funding, coordinated four EU grants, and received multiple prestigious awards, including fellowships from AIMBE, the International Union of Societies for Biomaterials Science and Engineering, and the Tissue Engineering and Regenerative Medicine International Society.

Q
Prof. José Carlos Rodríguez Cabello

Prof. José Carlos Rodríguez Cabello

Scientific Advisory Board

Dr. Rodríguez-Cabello is a Full Professor at the University of Valladolid, Spain, specializing in polymer physics and biomaterials science. He founded BIOFORGE in 1997, now a world-leading research group in recombinamers. His research focuses on biofunctional, smart, and customized protein polymers for advanced biomedical applications.

He has authored 200 peer-reviewed papers, 13 book chapters, 9 patents, leading to a h-index of 49. He has supervised 23 PhD students, 20 MSc students, and 7 postdoctoral fellows. Prof. Rodríguez-Cabello has coordinated numerous National and European research projects, securing over €8 million in funding over the last decade. He has been actively involved in scientific societies, journal editorial boards, and international conference committees, delivering 38 invited/keynote/plenary talks at major scientific events, including SIBB, TERMIS, ESB, and the World Polymer Congress.

Q
Dr. Matilde Alonso Rodrigo

Prof. Matilde Alonso Rodrigo

Scientific Advisory Board

Dr. Matilde Alonso Rodrigo, PhD in Chemical Sciences from the University of Valladolid, is a Full Professor at the University School of the University of Valladolid. She is a founding member of the Bioforge Group, recognized as a Group of Excellence by the Regional Government of Castilla y León. Her research focuses on recombinant elastin-like polymers, with more than 100 indexed publications leading to an h-index of 38 and six patents (three PCTs).

She has supervised many doctoral theses, receiving prestigious awards. Dr. Alonso Rodrigo has participated in 40+ research projects, including EU-funded programs like BioPolySurf (FP6) and Elastislet (H2020), and has led 12 projects funded by national, regional, and industry collaborations. She is also a co-founder of TECHNICAL PROTEINS NANOBIOTECHNOLOGY S.L., a University of Valladolid spin-off established in 2010.

Q